InvestSMART

Argent Biopharma Limited (ASX: RGT) - Announcements

Current share price for RGT : $0.032 0.002 (5.88%)+

ASX company news and announcements for Argent Biopharma Limited (RGT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Argent Biopharma Limited (RGT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Argent Biopharma Limited (RGT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Argent Biopharma Limited (RGT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$4 FDA-CVM Establish INAD File for CannEpil Veterinary Program 26 Aug 2026 9:50AM $0.039 $0.032 fallen by 17.95%
$4 Proposed issue of securities - RGT 11 Aug 2026 9:12AM $0.041 $0.032 fallen by 21.95%
$4 $250,000 in Funding Received under Financing Facility 11 Aug 2026 9:06AM $0.041 $0.032 fallen by 21.95%
$4 US Veterinary Development Programme for CannEpil Commences 6 Aug 2026 9:14AM $0.045 $0.032 fallen by 28.89%
$4 Notification of cessation of securities - RGT 3 Aug 2026 5:16PM $0.038 $0.032 fallen by 15.79%
$4 CannEpil Global Licence Expands into Veterinary Healthcare 31 Jul 2026 9:23AM $0.037 $0.032 fallen by 13.51%
$4 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jul 2026 8:25AM $0.050 $0.032 fallen by 36%
$4 Notification of cessation of securities - RGT 17 Jul 2026 5:31PM $0.055 $0.032 fallen by 41.82%
$4 s708A(12C)(e) Cleansing Notice 14 Jul 2026 2:53PM $0.059 $0.032 fallen by 45.76%
$4 Notification regarding unquoted securities - RGT 14 Jul 2026 2:45PM $0.058 $0.032 fallen by 44.83%
$4 Proposed issue of securities - RGT 14 Jul 2026 2:45PM $0.058 $0.032 fallen by 44.83%
$4 $350,000 in Funding Received under Financing Facility 14 Jul 2026 2:37PM $0.058 $0.032 fallen by 44.83%
$4 Application for quotation of securities - RGT 8 Jul 2026 6:25PM $0.068 $0.032 fallen by 52.94%
$4 RGT Executes Global CannEpil Licensing Deal for US$5.5M 7 Jul 2026 9:23AM $0.035 $0.032 fallen by 8.57%
$4 Long Term Aquiol Licensing and Supply Agreement 25 May 2026 9:06AM $0.038 $0.032 fallen by 15.79%
$4 Final Director's Interest Notice - GH 6 May 2026 9:02AM $0.037 $0.032 fallen by 13.51%
$4 Initial Director's Interest Notice - AC 6 May 2026 9:01AM $0.037 $0.032 fallen by 13.51%
$4 Appointment of Executive Director 6 May 2026 9:01AM $0.037 $0.032 fallen by 13.51%
$4 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2026 9:04AM $0.038 $0.032 fallen by 15.79%
$4 Completion of CannPal Asset Acquisition and Neuvis Option 13 Apr 2026 8:58AM $0.033 $0.032 fallen by 3.03%
$4 Change of Director's Interest Notice x 3 10 Apr 2026 6:22PM $0.033 $0.032 fallen by 3.03%
$4 s708A Cleansing Notice 10 Apr 2026 6:22PM $0.033 $0.032 fallen by 3.03%
$4 Notification regarding unquoted securities - RGT 10 Apr 2026 6:19PM $0.033 $0.032 fallen by 3.03%
$4 Application for quotation of securities - RGT 10 Apr 2026 6:18PM $0.033 $0.032 fallen by 3.03%
$4 Application for quotation of securities - RGT 10 Apr 2026 6:18PM $0.033 $0.032 fallen by 3.03%

1 - 25 of 169 results

Page 1 of 7

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.